Ipamorelin is characterized as selective, producing GH release with minimal cortisol and prolactin effects, unlike GHRP-6 and GHRP-2
Key properties: Stimulates GH release from the pituitary (not the hypothalamus) Does not significantly raise cortisol or prolactin Short half-life (~2 hours) produces a sharp, pulsatile GH release Does not block somatostatin (the hormone that inhibits GH release) Selective for GH minimal effect on other hormones The selectivity is what makes ipamorelin the preferred GHRP for most protocols
How the Sermorelin and Tesamorelin Stack Supports Overall Metabolic Balance The Sermorelin and Tesamorelin stack supports overall metabolic balance through growth hormone signaling
For patients whose primary goal is metabolic health improvement and visceral fat reduction rather than body recomposition, MOTS-c is often a better primary choice or a complementary addition to the CJC/Ipa stack
The increased potencies of the IGF-I variants may relate to the substantially increased plasma levels of IGF-binding proteins, particularly IGFBP-3, produced by the combined treatment of dexamethasone with IGF-I or the variants